Vnitřní lékařství 2/2020

P Ř EHLEDOVÉ Č LÁNKY Adipocytokíny a tyreopatie | 17 / Vnitř Lék 2020; 66(E-2): 13–18 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 21. Yldiz BO, Aksoy DY, Harmanci A, et al. Effects of l-thyroxine therapy on circulating lep- tin and adiponectin levels in subclinical hypothyroidism: a prospective study. Arch Med Res 2013; 44: 317–320. 22. Soriguer F, Valdes S, Morcillo S, et al. Thyroid hormone levels predict the change in body weight: a prospective study. Eur J Clin Invest 2011; 41: 1202-1209. 23. Ozcelik F, Yuksel C, Arslan E, et al. Relationship between visceral adipose tissue and adiponectin, inflammatory markers and thyroid hormones in obese males with hepatos- teatosis and insulin resistance. Arch Med Res 2013; 44: 273–280. 24. Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ re- ceptor. J Neurochem 2000; 74: 34–41. 25. O’Carroll AM, Selby TL, Palkovits M, et al. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim Biophys Acta 2000; 1492: 72–80. 26. Scott IC, Masri B, D’Amico LA, et al. The g protein-coupled receptor agtrl1b regulates early development of myocardial progenitors. Dev Cell 2007; 12: 403–413. 27. Zeng XX, Wilm TP, Sepich DS, et al. Apelin and its receptor control heart field formati- on during zebrafish gastrulation. Dev Cell 2007; 12: 391–402. 28. Xie H, Tang SY, Cui RR, et al. Apelin and its receptor are expressed in human osteob- lasts. Regul Pept 2006; 134: 118–125. 29. Principe A, Melgar-Lesmes P, Fernández-Varo G, et al. The hepatic apelin system: A new therapeutic target for liver disease. Hepatology 2008; 48: 1193–1201. 30. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764–1771. 31. Kechyn S, Barnes G, Howard L. Assessing dynamic changes in plasma apelin concent- ration in response to maximal exercise in man. Eur Respir J 2015; 46: PA2316. 32. Lambrecht NW, Yakubov I, Zer C, et al. Transcriptomes of purified gastric ECL and pa- rietal cells: identification of a novel pathway regulating acid secretion. Physiol Genomics 2006; 25: 153–165. 33. Sörhede Winzell M, Magnusson C, Ahrén B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept 2005; 131: 12–17. 34. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764–1771. 35. Yasar HY, Demirpence M, Colak A, et al. Serum irisin and apelin levels and markers of atherosclerosis in patients with subclinical hypothyroidism. Arch Endocrinol Metab 2019; 63: 16–21. 36. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presen- ting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198: 977–985. 37. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148: 4687–4694. 38. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821–1830. 39. Gong N, Gao C, Chen X, et al. Adipokine expression and endothelial function in sub- clinical hypothyroidism rats. Endocr Connect 2018; 7: 295–304. 40. Europemp. Anotace. (cit. 2018–09–17) Dostupné z www: <https://europepmc.org/ abstract/med/28872087>. Li Y, Chang J, Jiang T, et al. Serum level of chemerin and bone mineral density in patients with Graves disease. J Cent South Univ 2017; 42(8): e947-e952. Dostupné z DOI: <10.11817/j.issn.1672-7347.2017.08.012> 41. Carter JC, Church FC. Obesity and breast cancer: the roles of peroxisome proliferator- -activated receptor-γ and plasminogen activator inhibitor-1. PPAR Research 2009: 345320. 42. Wahrenberg H, Wennlund A, Hoffstedt J. Increased adipose tissue secretion of inter- leukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves’ hyperthyroidism. Eur J Endocrinol 2002; 146: 607–611. 43. Rosc D, Zastawna E, Drewniak W, et al. Plasminogen activators (tissue type t-PA, uroki- nase type u-PA) and plasminogen activator inhibitor type 1 (PAI-1) in Graves disease. Med Sci Monit 1998; 4: 975–978. 44. Davies PH, Black EG, Sheppard MC, et al. Relation between serum interleukin-6 and thyroid hormone concentrations in 270 hospital in-patients with non-thyroidal illness. CLin Endocrinol (Oxf) 1996; 44: 199–205. 45. Bartalena L, Brogioni S, Grasso L, et al. Interleukin-6: a marker of thyroid destructive process? J Clin Endocrinol Metab. 1994; 79: 1424–1427. 46. Ambati S, Kim HK, Yang KY, et al. Effects of leptin on apoptosis and adipogenesis in 3T3-L1 adipocytes. Biochem Pharmacol 2007; 73: 378–384. 47. Torgerson JS, Carlsson B, Stenlöf F, et al. A low serum leptin level at baseline and a large early decline in leptin predict a large 1-year weight reduction in energy-restricted obese humans. J Clin Endocrinol Metab 1999; 84: 4197–4203. 48. Näslund E, Andersson I, Degerblad M, et al. Associations of leptin, insulin resistan- ce and thyroid function with long-term weight loss in dieting obese men. J Intern Med 2000; 248: 299–308. 49. Reinehr T, Andler W. Thyroid hormones before and after weight loss in obesity. Arch Dis Child 2002; 87: 320–323. 50. Yoshida T, Momotani M, Hayashi M, et al. Serum leptin concentrations in patients with thyroid disorders. Clin Endocrinol (Oxf) 1998; 48: 299–302. 51. Nakamura T, Nagasaka S, Ishikawa S, et al. Association of hyperthyroidism with serum leptin levels. Metabolism 2000; 49: 1285–1288. 52. Escobar-Morreale HF, Escobar del Rey F, Morreale de Escobar G. Thyroid hormones influence serum leptin concentrations in the rat. Endocrinology 1997; 138: 4485–4488. 53. Zabrocka L, Klimek J, Swierczynski J. Evidence that triiodothyronine decreases rat se- rum leptin concentration by down-regulation of leptin gene expression in white adipo- se tissue. Life Sci 2006; 79: 1114–1120. 54. Mantzoros CS, Ozata M, Negrao AB, et al. Synchronicity of frequntly sampled thyrot- ropin (TSH) and leptin concentrations in healthy adults and leptin-deficient subjects: Evi- dence for possible partial TSH regulation by leptin in humans. J CLin Endocrinol Metab 2001; 86: 3284–3291. 55. Pinkney JH, Goodrick SJ, Katz J, et al. Leptin and the pituitary-thyroid axis: a compara- tive study in lean, obese, hypothyroid and hyperthyroid subjects. Clin Endocrinol (Oxf). 1998; 49: 583–588. 56. Valcavi R, Zini M, Peino R, et al. Influence of thyroid status on serum immunoreactive leptin levels. J Clin Endocrinol Metab. 1997; 82: 1632–1634. 57. Corbetta S, Englaro P, Giambona S, et al. Lack of effects of circulating thyroid hormone levels on serum leptin concentrations. Eur J Endocrinol 1997; 137: 659–663. 58. Leonhardt U. Serum leptin levels in hypo- and hyperthyroidism. Eur J Endocrinol 1998; 157: 75–79. 59. Soriguer F, Valdes S, Morcillo S, et al. Thyroid hormone levels predict the change in body weight: a prospective study. Eur J Clin Invest 2011; 41: 1202–1209. 60. Guzel S, Seven A, Guzel EC, et al. Visfatin, leptin, and TNF-α: Interrelated adipokines in insulin-resistant clinical and subclinical hypothyroidism. Endocr Res 2013; 38. Dostupné z DOI: <doi.org/10.3109/07435800.2012.760588 > 61. Bétry C, et al. Increased TSH in obesity: Evidence for a BMI-independent association with leptin. Diabetes Metab 2015; 41: 248–251. 62. Mazaki-Tovi M, Feuermann Y, Segev G, et al. Increased serum leptin and insulin con- centrations in canine hypothyroidism. Vet J 2010; 18: 109–114. 63. Macek Jílková Z, Pavelka S, Flachs P, et al. Modulation of type I iodothyronine 5’-deio- dinase activity in white adipose tissue by nutrition: possible involvement of leptin. Phys- iol Res 2010; 59: 61–69. 64. Luvizotto RA, Conde SA, Síbio MT, et al. Administration of physiologic levels of triio- dothyronine increases leptin expression in calorie-restricted obese rats, but does not in- fluence weight loss. Metabolism 2010; 59: 1–6. 65. Journals.Anotace. (cit. 2018–09–17) Dostupné z www: <https://journals.plos.org/ plosone/article?id=10.1371/journal.pone.0074856>. de Oliveira M, Luvizotto A, Olimpio RM, et al. Triiodothyronine increases mRNA and protein leptin levels in short time in 3T3- L1 adipocytes by PI3K pathway activation. PLoS One 2013; 8(9). Dostupné z DOI: <doi. org/10.1371/journal.pone.0074856> 66. Eray E, Sari F, Ozdem S, et al. Relationship between thyroid volume and iodine, lep- tin, and adiponectin in obese women before and after weight loss. Med Princ Pract 2011; 20: 43–46. 67. Gao CX, Yang B, Guo Q, et al. High thyroid-stimulating hormone level is associated with the risk of developing atherosclerosis in subclinical hypothyroidism. Horm Metab Res 2015; 47: 220–224. 68. Cerit ET, Akturk M, Altinova AE, et al. Evaluation of body composition changes, epi- cardial adipose tissue, and serum omentin-1 levels in overt hypothyroidism. Endocrine 2015; 49: 196–203. 69. Stumvoll M, Häring H. Resistin and adiponectin – of mice and men. Obesity 2002; 10: 1197–1199. 70. Nogueiras R, Guailillo O, Caminos JE, et al. Regulation of resistin by gonadal, thyroid hormone, and nutritional status. Obes Res 2003; 11: 408–414. 71. Krassas G E, Pontikides N, Loustis K, et al. Resistin levels in hyperthyroid patients be- fore and after restoration of thyroid function: relationship with body weight and body composition. Eur J Endocrinol 2005; 153: 217–221. 72. El Gawad SS, El Kenawy F, Mousa AA, et al. Plasma levels of resistin and ghre- lin before and after treatment in patients with hyperthyroidism. Endocr Pract 2012; 18: 376–381. 73. Krassas GE, Pontikides N, Loustis K, et al. Resistin levels are normal in hypothyroidism and remain unchanged after attainment of euthyroidism: relationship with insulin levels and anthropometric parameters. J Endocrinol Invest 2006; 29: 606–612. 74. Ziora, KT, Oswiecimska JM, Swietochowska E, et al. Assessment of serum levels resi- stin in girls with anorexia nervosa. Part II. Relationships between serum levels of resistin and thyroid, adrenal and gonadal hormones. Neuro Endocrinol Lett 2011; 32: 697–703. 75. Murphy K, Travers P, Walport M. Janeway’s Immunobiology. 7 th ed. Garland Science: New York (USA) 2008. 76. Díez JJ, Hernanz A, Medina S, et al. Serum concentrations of tumor necrosis factor- -alpha and soluble tumor necrosis factor-alpha receptor p55 in patients with hypothy- roidism and hyperthyroidism before and after normalization of thyroid function. Clin En- docrinol (Oxf) 2002; 57: 515–521. 77. Blüher M. Vaspin in obesity and diabetes: patophysiological and clinical significance. Endocrine 2012; 41: 176–182.